The MITD1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human Raji B lymphocyte line, designed to disrupt the MITD1 gene. MITD1 (Microtubule Interacting and Trafficking Domain containing 1) functions as a crucial component of the ESCRT-III complex. The polyclonal format includes a heterogeneous pool of edited cells with diverse allelic modifications, offering a versatile loss-of-function model without requiring single-cell cloning. This product provides a ready-to-use system for probing MITD1-dependent processes in a well-characterized Burkitt lymphoma background.
Raji cells, originally derived from an Epstein-Barr virus (EBV)-positive Burkitt lymphoma patient, are B lymphoblastoid cells that retain key humoral immune functions such as antigen presentation and antibody production. Their robust proliferation and extensively studied signaling networks have established them as a standard model for lymphoma research. The genetic tractability of Raji cells supports efficient CRISPR/Cas9 engineering, enabling the generation of polyclonal knockout populations that bypass clonal selection while preserving the heterogeneous editing outcomes essential for population-level studies.
MITD1 operates as an accessory factor within the ESCRT-III complex, where it interacts with CHMP1B and IST1 to facilitate intraluminal vesicle formation and membrane scission. Its recruitment is orchestrated by ubiquitination-dependent sorting signals, and it collaborates with the VPS4 ATPase to direct ubiquitinated membrane proteins into multivesicular bodies. During cytokinesis, MITD1 localizes to the midbody and mediates abscission through interactions with midbody components. Consequently, MITD1 disruption simultaneously impairs endosomal trafficking and the terminal phase of cell division.
In the Raji B lymphocyte context, MITD1 knockout perturbs ESCRT-dependent pathways that are critical for immune function and genomic stability. Lymphocytes rely on efficient endosomal sorting for antigen internalization and processing, processes that may be compromised upon MITD1 loss. Additionally, defective cytokinetic abscission can result in polyploidy and chromosomal instability, pathological features linked to Burkitt lymphoma progression. This model thus enables dissection of how ESCRT dysfunction contributes to B cell malignancies and to other disorders associated with endosomal traffic anomalies, including certain neurodegenerative conditions.
This product supports a broad range of experimental approaches. Western blotting and immunofluorescence microscopy validate MITD1 disruption and monitor ESCRT component redistribution, while flow cytometry quantifies cell cycle perturbations such as G2/M arrest and polyploidy. Endocytosis assays using fluorescent cargoes directly evaluate sorting defects, and RNA-seq captures transcriptome-wide changes. These applications make the MITD1 Knockout Raji Polyclonal Cells suitable for drug response profiling, functional genomics, and mechanistic investigations of membrane trafficking in lymphoma. For further details, please contact Ascent Research.
